首页> 美国卫生研究院文献>Open Forum Infectious Diseases >Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients
【2h】

Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients

机译:慢性病和免疫功能低下患者对H5N1病毒疫苗的神经氨酸酶抑制抗体反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Neuraminidase-inhibiting (NAi) antibodies have been reported to be an independent correlate of protection from influenza disease, but the NAi antibody response to influenza vaccination has never been assessed in chronically ill or immunocompromised participants. Using an enzyme-linked lectin assay, we demonstrated that 2 immunizations with a Vero cell culture-derived, whole-virus H5N1 A/Vietnam vaccine induces NAi antibodies in 94.3% of chronically ill and 83.8% of immunocompromised participants. A booster with a heterologous A/Indonesia H5N1 vaccine induced comparable NAi antibody titers in both groups and resulted in 100% seropositivity. These data support prepandemic H5N1 vaccination strategies for these highly vulnerable risk groups.
机译:据报道,神经氨酸酶抑制(NAi)抗体是预防流感疾病的独立相关因素,但从未在慢性病或免疫功能低下的参与者中评估过NAi抗体对流感疫苗的反应。使用酶联凝集素测定法,我们证明了用Vero细胞培养衍生的全病毒H5N1 A /越南疫苗进行的2次免疫接种可在94.3%的慢性病患者和83.8%的免疫受损参与者中诱导NAi抗体。异种A /印度尼西亚H5N1疫苗的加强免疫剂在两组中均诱导了类似的NAi抗体效价,并导致100%的血清阳性。这些数据支持针对这些高度脆弱的风险人群的大流行前H5N1疫苗接种策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号